Loading clinical trials...
Loading clinical trials...
A Phase 1 Dose Escalation and Expansion Study of ABL503, a Bispecific Antibody of 4-1BB and PD-L1, As a Single Agent in Subjects with Any Progressive Locally Advanced (unresectable) or Metastatic Solid Tumors
Conditions
Interventions
ABL503
Locations
8
United States
City of Hope
Duarte, California, United States
USC
Los Angeles, California, United States
UCLA
Santa Monica, California, United States
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, United States
NEXT Oncology
San Antonio, Texas, United States
Seoul National University Hospital
Seoul, South Korea
Start Date
April 1, 2021
Primary Completion Date
November 30, 2025
Completion Date
June 15, 2026
Last Updated
February 6, 2025
NCT07177937
NCT05919264
NCT07181681
NCT06257264
NCT07360314
NCT07539285
Lead Sponsor
ABL Bio, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions